[
  {
    "ts": null,
    "headline": "Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors",
    "summary": "PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (\"BMS\") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in",
    "url": "https://finnhub.io/api/news?id=11688ab2e767a40282111e7401a41b8eaf3b13fb96676ce4c699cd7d9f6b4c32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762264800,
      "headline": "Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors",
      "id": 137312512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (\"BMS\") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in",
      "url": "https://finnhub.io/api/news?id=11688ab2e767a40282111e7401a41b8eaf3b13fb96676ce4c699cd7d9f6b4c32"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Way Too Cheap At 7x P/E",
    "summary": "Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY stock is a compelling opportunity.",
    "url": "https://finnhub.io/api/news?id=574805906b001c4df58f670b559fb12cd39fb6f0759344782894b1f302b9304f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762243200,
      "headline": "Bristol-Myers Squibb: Way Too Cheap At 7x P/E",
      "id": 137311371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411224388/image_1411224388.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers' growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines. Read why BMY stock is a compelling opportunity.",
      "url": "https://finnhub.io/api/news?id=574805906b001c4df58f670b559fb12cd39fb6f0759344782894b1f302b9304f"
    }
  }
]